HHV6 R-GENE®REAL TIME PCR ASSAYS - ARGENE® TRANSPLANT RANGE
The power of true experience
CLINICAL CONTEXT1,2
Human herpesvirus 6 (HHV-6) is a DNA virus, member of the Herpesviridae family, that includes two species: HHV-6A and HHV-6B. This is an ubiquitous virus with a seroprevalence reaching more than 90% in adult population. Primary infection most often occurs before 2 years old, causing roseola infantum. After primo-infection, HHV-6 remains latent in various cells including monocytes, macrophages, endothelial cells, bone marrow progenitors and central nervous system cells. As a noticeable di� erence with other human herpesviruses, genomic HHV-6 DNA can be integrated into the cell chromosomes (ciHHV-6) in about 1% of the general population. During speci � c pathological states (e.g. immunocompromised patients), HHV-6 can be reactivated and impact several organs.
In transplant patients, HHV-6 reactivation may result in a wide clinical spectrum: bone marrow suppression, graft rejection, pneumonitis, encephalitis, hepatitis, fever, skin rash... Among these patients, hematopoietic stem cell transplant recipients are particularly at risk of developing an HHV-6 reactivation (about 50% within the � rst 4 weeks after cell transfer). Severe complications linked to this active infection include delayed engraftment, graft versus host disease, and HHV-6 encephalitis.
HHV6 R-GENE®
KEY FEATURES• Ready-to-use reagents
• Complete qualitative and quantitative kit
• Validated on most relevant sample types
• Validated with the major extraction and ampli� cation platforms
• for low to high throughput analysis
• Same procedure for all the ARGENE® TRANSPLANT kits
• Detect and quantify the 2 species HHV-6A & HHV-6B (without subtyping)
10-1
8 /
9315
783/
007/
GB/
B /
BIO
MER
IEU
X an
d th
e BI
OM
ERIE
UX
logo
, ARG
ENE,
EM
AG, e
asyM
AG a
nd R
-GEN
E ar
e us
ed, p
endi
ng a
nd/o
r reg
iste
red
trad
emar
ks b
elon
ging
to b
ioM
érie
ux, o
r one
of i
ts s
ubsi
diar
ies,
or o
ne o
f its
com
pani
es.
Any
othe
r nam
e or
trad
emar
k is
the
prop
erty
of i
ts re
spec
tive
owne
r / b
ioM
érie
ux S
.A. R
CS Ly
on 6
73 6
20 3
99 /
Prin
ted
in F
ranc
e / thera
/ RC
S Ly
on B
398
160
242
bioMérieux S.A. • 69280 Marcy l’Etoile • France • Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90www.biomerieux.com
OTHER ARGENE® TRANSPLANT KITS• EBV R-GENE® (69-002B) • CMV R-GENE® (69-003B) • HSV1 HSV2 VZV R-GENE® (69-004B) • ADENOVIRUS R-GENE® (69-010B) • BK Virus R-GENE® (69-013B) • Parvovirus B19 R-GENE® (69-019B)
REFERENCE1. Agut et al. Laboratory and clinical aspects of human herpesvirus 6 infections. Clinical Microbiology Reviews 2015; 28(2): 313-3352. Komaro� et al. Summary of the 10th International Conference on Human Herpesviruses-6 and -7 (HHV-6A, -6B, and HHV-7). Journal of Medical Virology 2017; 1-6
TECHNICAL INFORMATION ORDERING INFORMATION HHV6 R-GENE® - Ref.69-006B
Type of kit Real-time detection and quanti� cation kit
Gene target U57 gene coding for major capsid protein
Validated specimens Whole blood, Plasma, CSF, BAL
Validated extraction platforms EMAG®, NUCLISENS® easyMAG®, MagNA Pure 96, QIAsymphony SP
Validated ampli� cation platforms ABI 7500 Fast, ABI 7500 Fast Dx, LightCycler 480 (System II), Rotor-Gene Q, CFX96
Limit of Detection (LoD 95%) Whole blood, plasma, CSF, BAL: 2.3 log10 copies/mL
Quanti� cation Range Whole blood, plasma, CSF, BAL: 2.7 to 8.0 log10 copies/mL
Controls includedExtraction / Inhibition Control, Negative Control, Positive Control (QS3), 4 Quanti� cation Standards, Sensitivity Control
Number of tests 90 tests
Storage conditions -15°C / -31°C
Status For in vitro diagnostic use, CE-IVD marking